PROGESTERONE ENZYME IMMUNOASSAY TEST KIT Catalog Number: PS-1113 Enzyme Immunoassay for the PRINCIPLE OF THE TEST Quantitative Determination of Progesterone Concentration in
The progesterone EIA is based on the principle of
Human Serum
competitive binding between progesterone in the test
specimen and progesterone-HRP conjugate for a
constant amount of rabbit anti-progesterone. In the
FOR RESEARCH USE ONLY
incubation, goat anti-rabbit IgG-coated wells are
incubated with 25 µl progesterone standards, controls,
NOT FOR DIAGNOSTIC USE
samples, 100 µl progesterone-HRP Conjugate Reagent
and 50 µl rabbit anti-progesterone reagent at room
temperature (18-25°C) for 90 minutes. During the
PROPRIETARY AND COMMON NAMES
incubation, a fixed amount of HRP-labeled progesterone
competes with the endogenous progesterone in the
standard, sample, or quality control serum for a fixed
number of binding sites of the specific progesterone
NTENDED USE
antibody. Thus, the amount of progesterone peroxidase
For the quantitative determination of Progesterone
conjugate immunologically bound to the well
progressively decreases as the concentration of
progesterone in the specimen increases. INTRODUCTION
Unbound progesterone peroxidase conjugate is then
Progesterone is a C21 steroid which is synthesized from
removed and the wells washed. Next, a solution of TMB
both tissue and circulating cholesterol. Cholesterol is
Reagent is then added and incubated at room
transformed to pregnenolone which is then converted via
temperature for 20 minutes, resulting in the development
a combined dehydrogenase and isomerase to
of blue color. The color development is stopped with the
progesterone. The principle production sites are the
addition of Stop Solution, and the absorbance is
adrenals and ovaries and the placenta during pregnancy.
measured spectrophotometrically at 450 nm. The
The majority of this steroid is metabolized in the liver to
intensity of the color formed is proportional to the
pregnanediol and conjugated as a glucuronide prior to
amount of enzyme present and is inversely related to the
amount of unlabeled progesterone in the sample. A
standard curve is obtained by plotting the concentration
Progesterone exhibits a wide variety of end organ
of the standard versus the absorbance. The
effects. The primary role of progesterone is exhibited by
progesterone concentration of the specimens and
the reproductive organs. In males, progesterone is a
controls run concurrently with the standards can be
necessary intermediate for the production of
corticosteroids and androgens. In females,
progesterone remains relatively constant throughout the
REAGENTS
follicular phase of the menstrual cycle. The
concentration then increases rapidly following ovulation
Materials provided with the kit:
and remains elevated for 4-6 days and decreases to the
Goat Anti-Rabbit IgG-coated microtiter wells, 96
initial level 24 hours before the onset of menstruation. In
pregnancy, placental progesterone production rises
Progesterone Reference Standards: 0, 0.5, 3.0, 10,
steadily to levels of 10 to 20 times those of the luteal
25, and 50 ng/ml. Liquids, 0.5 ml each, ready to
Progesterone measurements are thus performed to
Rabbit Anti-Progesterone Reagent (pink color), 7 ml.
determine ovulation as well as to characterize luteal
Progesterone-HRP Conjugate Concentrate (11x),
phase defects. Monitoring of progesterone therapy and
early stage pregnancy evaluations comprise the
Progesterone-HRPConjugate Diluent, 13 ml
remaining uses of progesterone assays.
Progesterone Control 1, Liquid, 0.5 ml, Ready to
Progesterone Control 2, Liquid, 0.5 ml, Ready to
For research use only. Not for diagnostic or therapeutic use. Prolias Technologies products may not be sold or modified for resale or used to manufacture commercial products without prior written approval by Prolias Technologies. If you are not satisfied with the product please contact us.
3. Samples with expected progesterone concentrations
over 50 ng/ml may be quantitated by dilution with
Materials required but not provided:
• Precision pipettes: 25 µl, 50 µl, 100 µl, 200 µl, and
ASSAY PROCEDURE
1. Secure the desired number of coated wells in
2. Dispense 25 µl of standards, specimens and
3. Dispense 100 µl of Working Progesterone- HRPConjugate Reagent into each well.
4. Dispense 50 µl of rabbit anti-progesterone
WARNINGS AND PRECAUTIONS FOR USERS
Test methods are not available which can offer complete
5. Thoroughly mix for 30 seconds. It is very
a s s u r a n c e t h a t H e p a t i t i s B v i r u s , H u m a n
important to mix them completely.
Immunodeficiency Virus (HIV/HTLV-III/LAV), or other
6. Incubate at room temperature (18-25°C) for 90
infectious agents are absent from the reagents in this kit.
Therefore, all human blood products, including samples,
7. Rinse and flick the microwells 5 times with
should be considered potentially infectious. Handling
distilled or deionized water. (Please do not use
and disposal should be in accordance with the
procedures defined by an appropriate national biohazard
8. Dispense 100 µl of TMB Reagent into each well.
safety guideline or regulation, where it exists (e.g., USA
Center for Disease Control/National Institute of Health
9. Incubate at room temperature (18-25°C) for 20
Manual, “Biosafety in Microbiological and Biomedical
10. Stop the reaction by adding 100 µl of Stop
AMPLE PREPARATION
11. Gently mix 30 seconds. It is important to make sure that all the blue color changes to yellow
2. No special pretreatment of sample is necessary.
3. Serum samples may be stored at 2-8°C for up to 24
12. Read absorbance at 450 nm with a microtiter
hours, and should be frozen at −10°C or lower for
well reader within15 minutes.
longer periods. Do not use grossly hemolyzed or
CALCULATION OF RESULTS
4. Please note: Samples containing sodium azide 1. Calculate the mean absorbance value (A
each set of reference standards, controls and
STORAGE OF TEST KIT AND INSTRUMENTATION 2. Construct a standard curve by plotting the mean
absorbance obtained for each reference standard
Unopened test kits should be stored at 2-8°C upon
against its concentration in ng/ml on a linear-linear
receipt and the microtiter plate should be kept in a
graph paper, with absorbance values on the vertical
sealed bag with desiccants to minimize exposure to
or Y axis, and concentrations on the horizontal or X
damp air. Opened test kits will remain stable until the
expiration date shown, provided it is stored as described
3. Use the mean absorbance values for each specimen
above. A microtiter plate reader with a bandwidth of 10
to determine the corresponding concentration of
nm or less and an optical density range of 0-3 O.D. at
Progesterone in ng/ml from the standard curve.
450 nm wavelength is acceptable for use in absorbance
4. Any values obtained for diluted samples must be
further converted by applying the appropriate dilution
REAGENT PREPARATION
1. All reagents should be brought to room temperature
EXAMPLE OF STANDARD CURVE
Results of a typical standard run with optical density
2. To prepare Working Progesterone-HRP
readings at 450 nm shown in the Y axis against
Conjugate Reagent, add 0.1 ml of Progesterone-
Progesterone concentrations shown in the X axis. Note: HRP Conjugate Concentrate (11x) to 1.0 ml of
This standard curve is for the purpose of illustration only,
Progesterone-HRP Conjugate Diluent (1:10
and should not be used to calculate unknowns. Each
dilution) and mix well. The amount of conjugate
laboratory must provide its own data and standard curve
diluted depends on your assay size. Discard the excess after use.
For research use only. Not for diagnostic or therapeutic use. Prolias Technologies products may not be sold or modified for resale or used to manufacture commercial products without prior written approval by Prolias 2Technologies. If you are not satisfied with the product please contact
replicate measurements of six different serum
samples over a series of individually calibrated
assays. Between-assay variability is shown
Absorbance (450 nm) Progesterone Conc. (ng/ml) 3. Linearity Study
Four samples were serially diluted to determine
linearity. The mean linearity was 105.9%. EXPECTED VALUES Dilution Expected Conc. Observed Conc. % Expected
Each laboratory should establish its own normal range
based on the sample population. The Progesterone EIA
Undiluted
was performed on randomly selected laboratory
samples. The following information is cited from
Prepubertal (children) 0.07 − 0.52 ng/ml
Females: follicular phase 0.15 – 0.70 ng/ml
Mean = 113.8% Undiluted PERFORMANCE CHARACTERISTICS Mean = 97.9% 1. Sensitivity
The minimum detectable concentration of the
Progesterone ELISA assay as measured by 2
Undiluted 2. Precision
Within-run precision was determined by replicate
determinations of four different serum samples
Mean = 95.1%
in one assay. Within-assay variability is shown
Undiluted
For research use only. Not for diagnostic or therapeutic use. Prolias Technologies products may not be sold or modified for resale or used to manufacture commercial products without prior written approval by Prolias 3Technologies. If you are not satisfied with the product please contact
LIMITATIONS OF THE PROCEDURE
1. Reliable and reproducible results will be obtained
when the assay procedure is carried out with a
complete understanding of the package insert
instructions and with adherence to good laboratory
2. The wash procedure is critical. Insufficient washing
Mean = 116.9%
will result in poor precision and falsely elevated
3. Serum samples demonstrating gross lipemia, gross
hemolysis, or turbidity should not be used with this
4. Recovery Study
Various serum samples of known Progesterone
QUALITY CONTROL
levels were combined and assayed in duplicate.
Good laboratory practice requires that controls are run
with each calibration curve. A statistically significant
number of controls should be assayed to establish mean
EXPECTED OBSERVED % RECOVERY
values and acceptable ranges to assure proper
[Progesterone] [Progesterone]
We recommend using Bio-Rad Lyphochek Immunoassay
Control Sera as controls. The Progesterone EIA kit also
provides with internal controls, Level 1 and 2. REFERENCES
Radwanska, E., Frankenberg, J., and Allen, E.,
Plasma progesterone levels in normal and abnormal
early human pregnancy. Fertility and Sterility, 1978;
5. Specificity
2. Autrere,M.B., and Benson, H., Progesterone: An
The following materials have been checked for cross
overview and recent advances, J. Par. Sci., 1976;
reactivity. The percentage indicates cross reactivity
at 50% displacement compared to Progesterone.
3. March, C.M., Goebelsmann, U., Nakamura, R.M.,
and Mishell, D.R. Jr., Roles of estradiol and
Data on the cross-reactivity for several endogenous
progesterone in eliciting the midcycle luteinizing
and pharmaceutical steroids are summarized in the
hormone and follicle-stimulating hormone surges, J. Clin. Endo. Metab., 1979; 49, 507-513.
4. Ross, G.T., Vande Wiele, R.L., and Frantz, A.G.,
Cross-reactivity (%) = Observed Progesterone
The Ovaries and the breasts. In: Williams, R.H., ed.,
Textbook of Endocrinology. Saunders Company,
5. Chattoraj, S.C., Endocrine function. In: Tietz, N.W.,
Cross-Reactivity
ed., Fundamentals of Clinical Chemistry. Saunders
Company, Philadelphia; 1976: 699-823.
6. Shepard, M.K., and Senturia, Y.D., Comparison of
serum progesterone and endometrial biopsy for
confirmation of ovulation and evaluation of luteal
function. Fertility and Sterility, 1977; 28: 541-548.
7. Johansson, E.D.B., and Jonasson, L.-E.,
Progesterone levels in amniotic fluid and plasma
from women: I. Levels during normal pregnancy.
Acta Obstet. Gynec. Scand., 1971; 50: 339-343.
8. USA Center for Disease Control/National Institute of
Health Manual, “Biosafety in Microbiological and
Biomedical Laboratories"” 1984.
9. Tietz, N.W. ed., Clinical Guide to Laboratory Tests,
3rd Edition, W.B. Saunders, Co., Philadelphia, 1995:
10. ICN Guide to Endocrine Testing. Diagnostic Division,
For research use only. Not for diagnostic or therapeutic use. Prolias Technologies products may not be sold or modified for resale or used to manufacture commercial products without prior written approval by Prolias 4Technologies. If you are not satisfied with the product please contact
Memorias II Congreso Latinoamericano de Ingeniería Biomédica, Habana 2001, Mayo 23 al 25, 2001, La Habana, Cuba RADIATION ABSORBED DOSES AND SAFETY OF THE HUMANIZED MONOCLONAL ANTIBODY H-R3 LABELED WITH 99MTC Leonel A. Torres, Marco A. Coca, Maria E. Solano, Alejandro Perera, Juan F. Batista, Abel Hernandez, TaniaCrombet, Marilyn Perez, Mayra Ramos, Elvia L Sanchez, Susana Romero, Vice